首页> 外国专利> recombinant plasmid dna pvn22 which the biosynthesis of human leukozytärem interferon amp; alpha; - i1 encoded and strain pseudomonas sp.31 (containing pvn22) as a producer of human leukozytärem inte

recombinant plasmid dna pvn22 which the biosynthesis of human leukozytärem interferon amp; alpha; - i1 encoded and strain pseudomonas sp.31 (containing pvn22) as a producer of human leukozytärem inte

机译:重组质粒dna pvn22,可生物合成人白细胞介素α。 -作为人leukozytäreminte的生产者的i1编码品系假单胞菌sp.31(包含pvn22)

摘要

PCT No. PCT/SU87/00052 Sec. 371 Date Dec. 15, 1987 Sec. 102(e) Date Dec. 15, 1987 PCT Filed Apr. 29, 1987 PCT Pub. No. WO87/06613 PCT Pub. Date Nov. 5, 1987.A recombinant plasmid DVA pVN22 coding the biosynthesis of a human leukocyte interferon alpha -I1 having size of 10.85 t.p.b. and consisting of the following units: EcoRI-HindIII-a fragment of the plasmid pAYC37 with the size of 9.45 t.p.b., HindIII-EcoRI-a fragment with the size of 1.4 t.p.b. consisting of the following members: a fragment of DNA with the size of 0.25 t.p.b. with the regulatory range of gene D of the phague phi x174 and the first codons of the gene of interferon gene of interferon alpha -I1 with the size of 0.5 t.p.b., a region of the human genome DNA with the size of 0.65 t.p.b.; it has the following genetic markers: genome ApR ensuring resistance against ampicillin, genome SmR ensuring resistance to streptomycin; contains unique regions of recognition of restrictases: Hind III-O; EcoRI-1.4 t.p.b., BamHI-10.82 t.p.b., it is deposited at the collection of culture of microogranisms of the A11-Union Research Institute of Antibiotics and registered under the entry No. 1788I. A strain Pseudomonas Sp. 31 (pVN22)-producer of a human leukocyte interferon alpha -I1 containing a recombinant plasmid DNA pVN22 produced by the method of genetic engineering by introducing said plasmid into bacteria of the genus Pseudomonas, deposited at the collection of cultures of microoorganisms of the A11-Union Research Institute of Antibiotics on 02.04.86 and registered under the entry No. 1788A.
机译:PCT号PCT / SU87 / 00052第二部分371日期1987年12月15日102(e)日期:1987年12月15日; PCT申请日:1987年4月29日。 PCT公开号WO87 / 06613。 1987年11月5日,DVA pVN22重组质粒,其编码人白细胞干扰素α-I1的生物合成,大小为10.85t.p.b。并且由以下单元组成:EcoRI-HindIII-质粒pAYC37的片段,其大小为9.45t.p.b.,HindIII-EcoRI-a片段的大小为1.4t.p.b。由以下成员组成:0.25 t.p.b的DNA片段。 ;具有噬菌体phi x174的基因D的调节范围和干扰素α-I1的干扰素基因的基因的第一个密码子,大小为0.5t.p.b.,是人类基因组DNA的一个区域,大小为0.65t.p.b .;它具有以下遗传标记:基因组ApR确保对氨苄青霉素具有抗性,基因组SmR确保对链霉素具有抗性;包含限制酶识别的独特区域:Hind III-O; EcoRI-1.4 t.p.b.,BamHI-10.82 t.p.b.,保藏在A11-联合抗生素研究所的微菌种培养物中,并在条目号1788I下注册。假单胞菌菌株。 31(pVN22)-人白细胞干扰素α-I1的生产者,其含有通过基因工程的方法产生的重组质粒DNA pVN22,该基因通过将所述质粒引入假单胞菌属细菌中,保藏在A11-微生物的培养物上。联合抗生素研究所在02.04.86处注册,条目号1788A。

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号